title: Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors.
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D043168:Angiostatins; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000235:genetics; D003094:Collagen / Q000494:pharmacology; D043169:Endostatins; D016228:Endothelial Growth Factors; D004730:Endothelium, Vascular / Q000166:cytology; D019317:Evidence-Based Medicine; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D010446:Peptide Fragments / Q000494:pharmacology; D010958:Plasminogen / Q000494:pharmacology; D012106:Research; D013234:Stem Cells; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5
chemical_list: D020533:Angiogenesis Inhibitors; D043168:Angiostatins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D015820:Cadherins; D003094:Collagen; D043169:Endostatins; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010446:Peptide Fragments; D010958:Plasminogen; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099152:Cadherin 5